alexa Efficacy Of A Mixture Of Synthetic Peptides Overlapping The Conserved CBD1 Epitope In Gp41 Of HIV-1 To Protect Against SHIV162P3 Rectal Challenge In Cynomolgus Macaques | 9818
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Vaccines & Vaccination
July 29-31, 2013 Embassy Suites Las Vegas, NV, USA

Ara Hovanessian
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.016
Abstract
T he synthetic CBD1 peptide corresponding to the conserved caveolin-1 binding domain of HIV-1 glycoprotein gp41 (CBD1 epitope: CSLEQIWNNMTWMQWDK) elicits the production of antibodies in rabbits, mice, and macaques that inhibit infection of primary CD4+ T lymphocytes by various primary HIV-1 isolates. In a detailed study in mice we then showed that peptides overlapping the caveolin-1 binding motif (CBM: IWNNMTWMQW) containing the N-terminal conserved isoleucine residue, when fused to a T helper epitope, induce high titered HIV-neutralizing antibodies. Interestingly, immune sera raised against a given peptide do not cross-react with related CBM-derived peptides, thus suggesting the existence of distinct neutralizing determinants, which probably reflect the dynamic conformational features of the CBD1 epitope in gp41. CBD1- and CBM-based peptides therefore provide specific immunogens for an efficient vaccine preparation against HIV/AIDS infection. In our current study in cynomolgus macaques, the efficacy of the CBD1-based peptide-cocktail vaccine-formulation was evaluated in cynomolgus macaques by challenging the vaccinated animals with a replication competent simian/human immunodeficiency chimera virus (SHIV) that expresses HIV-1 envelope glycoproteins. For this purpose, animals were vaccinated at week 0, 4, 10, and 16 with a preparation containing a mixture of CBM-based peptides fused to the Gag 298-312 epitope, the CBD1 peptide, the TetA830 peptide, and adjuvants CpG and montanide ISA 51. Once every two weeks, vaccinated animals were monitored for the humoral and cellular immune response, while during the SHIV challenge period they were also monitored for the plasma viral load using quantitative RT-PCR and analyzed for the average relative distribution of T-cell subsets. All immunized macaques responded by the production of high tittered and CBD1-based peptide specific antibodies. Six months after the fourth vaccine boost, six control and five vaccinated animals were challenged by repeated exposure to SHIV162P3 (NIH) via the mucosal rectal route. All of the six control animals were infected after 1-3 challenges with SHIV. Among the five vaccinated macaques, three became infected with a slight delay after 2-3 days; one became infected only after nine weakly challenges, whereas one resisted nine weakly SHIV challenges. The protection of vaccinated compared to the control animals is significant; p=0.039, Fisher?s exact test. Analyses of CD4 and CD8 T cell dynamics indicated that whereas in non-vaccinated group CD4 T cell counts decrease at days 14 and 21, animals which received vaccine maintained CD4 T cell counts or even increase compared before infection. Analyses by flow cytometry of CD4 T cell subsets using the markers CD28 and CD95 demonstrated that CM memory cells (CD95+CD28+), which are considered to be associated with better protection are not depleted in vaccinated monkeys during the acute phase of infection. No difference was observed in effector memory (CD95+CD28-) and na?ve CD4 T cells (CD95-CD28+). Most importantly challenge with SHIV boosted at once the capacity of CD4 T cells in response to specific antigen stimulation. Therefore, one week after SHIV challenge of vaccinated macaques, there is antigen specific memory T-cell response; i.e. there is a recall memory T cell response induced by the native CBD1 epitope presented by the input SHIV gp41 used as a challlenge. The detection of specific CD4 T cells against the CBD1-based peptides revealed the potentiality of our vaccine strategy. These results and the conservation of CBD1 epitope among all viral isolates, provide promising perspectives for the use of our CBD1-based vaccine cocktail preparation as an efficient B-cell epitope vaccine candidate for HIV/AIDS. Moreover, as natural antibodies against the CBD1-epitope are not detectable in HIV-infected individuals, CBD1-based vaccines could have applications as a therapeutic vaccine in AIDS patients
Biography
Ara Hovanessian (Director of Research 1, CNRS) has completed his Ph.D. at the age of 30 years from King?s College, University of London with the thesis research work at the National Institute for Medical Research, Mill Hill. Then as a senior investigator, he spent 26 years at the ?Institut Pasteur? in close collaboration with Luc Montagnier. Since 2004, he is at CNRS-Universit? Paris Descartes where he conducts two major projects: 1) on the development of a synthetic vaccine for AIDS, and 2) on the development of synthetic peptides for cancer therapy. His research discoveries include: The interferon-induced 2?-5? oligoadenylate synthetase and protein kinase PKR, HIV-2 glycoproteins, Inhibitors of HIV entry, synthetic vaccines against HIV, surface-nucleolin as a target in cancer therapy. He has several patents, and published more than 190 scientific articles (PubMed) 75% of which he is the first or the last author.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version